Patents for A61P 35 - Antineoplastic agents (221,099)
07/2010
07/22/2010US20100184677 Use of the human pancreatic polypeptide as a therapeutic agent
07/22/2010US20100184676 Use of a peptide as a therapeutic agent
07/22/2010US20100184675 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
07/22/2010US20100184674 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent
07/22/2010US20100184673 Use of parathyroid hormone ( 1-34 ) as anti-hiv agent
07/22/2010US20100184671 Binding molecules for the treatment of myeloid cell malignancies
07/22/2010US20100184668 method of treating abnormal angiogenesis via the bai family of proteins and their protein fragments
07/22/2010US20100184667 Modified plasminogen activator inhibitor type-1 molecule and methods based thereon
07/22/2010US20100184661 Conjugate comprising angiostation or its fragment, the method for producing the conjugate and use thereof
07/22/2010US20100184652 Peptide inhibitors of abl kinases
07/22/2010US20100184651 Targeted fusion proteins for cancer therapy
07/22/2010US20100184646 Melanocortin receptor ligands modified with hydantoin
07/22/2010US20100184645 Stitched polypeptides
07/22/2010US20100184636 Method of Regulating Mammalian Target-of-Rapamycin Activity by Interaction Between Phospholipase D and Raptor
07/22/2010US20100184215 Modified thioredoxin
07/22/2010US20100183749 Topically active steroids for use in radiation and chemotherapeutics injury
07/22/2010US20100183743 Benzthiazole inhibitors of poly(adp-ribose)polymerase
07/22/2010US20100183742 Phosphoramidate alkylator prodrugs for the treatment of cancer
07/22/2010US20100183740 Potent Inhibitory Effect of Zinc in Combination with Sulforaphane on Cancer Cell Growth
07/22/2010US20100183728 Nanoparticle comprising rapamycin and albumin as anticancer agent
07/22/2010US20100183726 Compositions and methods for treating cancer with dacarbazine nanoemulsions
07/22/2010US20100183713 Gastrointestinal-specific multiple drug release system
07/22/2010US20100183705 Phospholipid-analogous compounds
07/22/2010US20100183702 Therapies For Cancer Using RLIP76
07/22/2010US20100183685 Tumor and infectious disease therapeutic compositions
07/22/2010US20100183650 Antigen Delivery Vectors and Constructs
07/22/2010US20100183643 Cancer vaccines containing epitopes of oncofetal antigen
07/22/2010US20100183642 Novel multimeric cd40 ligands, method for preparing same and use thereof for preparing drugs
07/22/2010US20100183637 fusion molecule based on novel taa variant
07/22/2010US20100183635 Glycosylated specificity exchangers
07/22/2010US20100183632 Antibody Therapy For Modulating Function Of Intestinal Receptors
07/22/2010US20100183631 Antibodies Directed to HER-3 and Uses Thereof
07/22/2010US20100183630 Tat-005 and Methods of Assessing and Treating Cancer
07/22/2010US20100183621 Fully human antibodies against human 4-1BB
07/22/2010US20100183616 Antibodies against interleukin-1 beta
07/22/2010US20100183615 Cross-species-specific bispecific binders
07/22/2010US20100183612 Methods of treatment using ctla4 mutant molecules
07/22/2010US20100183609 Taci-immunoglobulin fusion proteins
07/22/2010US20100183606 Monocyclic heterocycles as kinase inhibitors
07/22/2010US20100183604 Preventive/remedy for cancer
07/22/2010US20100183603 Compositions and Methods for the Treatment of Cancer
07/22/2010US20100183601 Combination of Aurora Kinase Inhibitors and Anti-CD20 Antibodies
07/22/2010US20100183600 RAF Inhibitors and Their Uses
07/22/2010US20100183599 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
07/22/2010US20100183595 Antibody against secreted N-terminal peptide of GPC3 present in blood or C-terminal peptide of GPC3
07/22/2010US20100183594 Steroid-sparing methods of treating brain edema
07/22/2010US20100183593 Gene Polymorphisms Predictive for Dual TKI Therapy
07/22/2010US20100183588 Mutated Netrin-4, Fragments Thereof And Their Use As Medicines
07/22/2010US20100183585 Methods and compositions for treating tumors and metastases through the modulation of latexin
07/22/2010US20100183581 Compositions and Methods for Modulating Blood-Brain Barrier Transport
07/22/2010US20100183573 membrane polypeptide for use in designing therapeutic for proliferative, inflammatory, skin, arthritic, cardiovascular and autoimmune disorders; cancer, immunological-related, blood-related and skin-related disorders
07/22/2010US20100183570 Non-embryonic stem cells and uses thereof
07/22/2010US20100183567 Novel Mammalian Multipotent Stem Cells and Compositions, Methods of Preparation and Methods of Administration Thereof
07/22/2010US20100183564 Compounds that expand hematopoietic stem cells
07/22/2010US20100183560 Angiogenesis-modulating compositions and uses
07/22/2010US20100183558 Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
07/22/2010US20100183550 Benzothienopyridines For Use As Inhibitors Of EG5 Kinesin
07/22/2010US20100183548 Tweak receptor
07/22/2010US20100183545 Targeted cargo protein combination therapy
07/22/2010US20100183544 Method of treatment
07/22/2010US20100183542 Synergism Between Activated Immune Cells and Conventional Cancer Therapies
07/22/2010US20100183517 Peptidomimetic Inhibitors Of PSMA, Compounds Comprising Them, And Methods Of Use
07/22/2010US20100183511 Small peptides specifically bind to colorectal cancers
07/22/2010US20100183508 Radioactive mixture and manufacturing method thereof
07/22/2010US20100183507 Tumor markers in ovarian cancer
07/22/2010US20100183506 Antigen associated with lung cancers and lymphomas
07/22/2010US20100183505 Immunoconjugate for human cd66 for the treatment of multiple myeloma and other haematological malignancies
07/22/2010US20100183504 Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
07/22/2010DE102009005193A1 Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren New heterocyclic compounds as MetAP-2 inhibitors
07/22/2010CA2758030A1 Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
07/22/2010CA2750009A1 Imidazothiazole derivatives having proline ring structure
07/22/2010CA2749496A1 Compositions and methods of use
07/22/2010CA2747837A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
07/22/2010CA2747835A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
07/21/2010EP2208784A1 Cell proliferation inhibitors containing anti-glypican 3 antibody
07/21/2010EP2208737A1 Complement factor H-derived short consensus repeat-antibody constructs
07/21/2010EP2208731A1 Process for preparation of 1,2-diamino-cyclohexane-platinum(II) complexes
07/21/2010EP2208725A1 Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications
07/21/2010EP2208721A1 Histone deacetylase inhibitor, composition and use thereof
07/21/2010EP2208499A1 Nucleic acid capable of regulating the proliferation of cell
07/21/2010EP2208497A1 Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
07/21/2010EP2207875A1 Antigen-specific t-cell preparations from bone marrow
07/21/2010EP2207819A1 Anti-microbial polymers and their compositions
07/21/2010EP2207810A1 Compositions affecting hyaluronic acid mediated activity
07/21/2010EP2207809A1 Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
07/21/2010EP2207803A1 Cd9-specific human antibodies
07/21/2010EP2207791A1 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
07/21/2010EP2207786A1 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors
07/21/2010EP2207781A1 Thiazolopyrimidine p13k inhibitor compounds and methods of use
07/21/2010EP2207777A2 Polymorphs of dasatinib and process for preparation thereof
07/21/2010EP2207774A1 Triazole derivatives as scd inhibitors
07/21/2010EP2207772A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor
07/21/2010EP2207562A1 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
07/21/2010EP2207560A2 Use of fibronectin fragment (196-203) as a therapeutic agent
07/21/2010EP2207548A1 Breast cancer therapy
07/21/2010EP2068894B1 Use of cis-rhenium (iii) diadamantate compounds for potentiating the antitumoral activity of platinium complexes
07/21/2010EP1940840B1 6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof
07/21/2010EP1809622B1 Inhibitors of the interaction between mdm2 and p53
07/21/2010EP1751128B1 Chromene-derivatives with anti-tubulin and vascular targeting activity
07/21/2010EP1742623B1 2-methylthiazolidine-2,4-dicarboxylic acid-containing combination preparations